Please assess the completion status of the following clinical trial:

Trial Title: A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Children less than (\<) 12 years of age, with allowance for participants 12 to 17 years of age who weigh \<40 kilograms (kg) (Cohort A only); and participants \<2 years of age will be allowed to participate only after the protocol-defined interim data review criteria are met (Cohort A only)~* Diagnosis of congenital hemophilia A of any severity and documented history of high-titer inhibitor (that is \[i.e.\], greater than or equal to \[\>/=\] 5 bethesda units \[BU\])~* Requires treatment with bypassing agents~* Adequate hematologic, hepatic, and renal function~Exclusion Criteria:~* Inherited or acquired bleeding disorder other than hemophilia A~* Ongoing (or planning to receive during the study) immune tolerance induction (ITI) therapy or prophylaxis treatment with FVIII~* Previous (in the past 12 months) or current treatment for thromboembolic disease or signs of thromboembolic disease~* Other disease that may increase risk of bleeding or thrombosis~* History of clinically significant hypersensitivity associated with monoclonal antibody therapy or components of the emicizumab injection~* Known infection with human immunodeficiency virus (HIV) or hepatitis B or C virus~* Use of systemic immunomodulators at enrollment or planned use during the study period~* Planned surgery (excluding minor procedures such as tooth extraction or incision and drainage) during the study~* Inability (or unwillingness by caregiver) to receive (allow receipt of) blood or blood products (or any standard-of-care treatment for a life-threatening condition)~* Participants who are at high risk for thrombotic microangiopathy (TMA) (e.g., have a previous medical or family history of TMA), in the investigator's judgement

- Gender: ALL
- Minimum Age: None
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Cohort A: 1.5 mg/kg Emicizumab QW (Type: EXPERIMENTAL): Participants will receive emicizumab at a loading dose of 3 milligrams per kilogram (mg/kg) QW SC for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg QW SC for a minimum of 52 weeks, or until unacceptable toxicity, discontinuation from the study due to any cause, or other criteria set forth in the protocol, whichever occurs first.
- Cohort B: 3 mg/kg Emicizumab Q2W (Type: EXPERIMENTAL): Participants will receive emicizumab at a loading dose of 3 mg/kg QW SC for the first 4 weeks followed by a maintenance dose of 3 mg/kg every 2 weeks (Q2W) SC for a minimum of 52 weeks, or until unacceptable toxicity, discontinuation from the study due to any cause, or other criteria set forth in the protocol, whichever occurs first.
- Cohort C: 6 mg/kg Emicizumab Q4W (Type: EXPERIMENTAL): Participants will receive emicizumab at a loading dose of 3 mg/kg QW SC for the first 4 weeks followed by a maintenance dose of 6 mg/kg every 4 weeks (Q4W) SC for a minimum of 52 weeks, or until unacceptable toxicity, discontinuation from the study due to any cause, or other criteria set forth in the protocol, whichever occurs first.

Based on this trial design, predict the completion outcome and termination type (if applicable).